This bill reauthorizes the Kay Hagan Tick Act by amending two provisions of the Public Health Service Act that underpin the national strategy and federal support for state and local response to tick‑borne diseases. It makes three targeted textual changes: it modifies statutory language about who helps shape the national strategy, it expands an enumerated program objective to emphasize operational capacity, and it lengthens the statutory authorization window for existing programs.
For professionals who manage public health programs, the bill preserves the legal authority for federal coordination and grants but leaves funding decisions to the appropriations process. The edits increase administrative flexibility but raise implementation questions about governance, stakeholder representation, and what measures will be used to translate the expanded operational language into funded activities.
At a Glance
What It Does
Amends two Public Health Service Act provisions that implement the Kay Hagan Tick Act: it alters language describing who participates in national strategy development, inserts an explicit operational capacity goal, and updates the statutory authorization period for covered programs. The changes are textual and do not set funding levels.
Who It Affects
Federal public health agencies that run and oversee tick‑borne disease programs, state and local health departments that apply for and use federal support, academic/regional centers involved in research and clinical guidance, and clinical/public health laboratories that support surveillance and response.
Why It Matters
The bill preserves program continuity while shifting legal language toward operational readiness (surveillance, reporting, prevention, response) and giving agencies more flexibility on governance. That matters for planning, grant priorities, and the scope of CDC technical assistance.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Kay Hagan Tick Act created statutory authority for a national strategy and regional centers of excellence to address tick‑borne diseases. This bill leaves those program frameworks intact while nudging their focus toward practical readiness: more emphasis on the ability to find and report cases, prevent spread, and respond to outbreaks.
For program managers, that signals an expectation of measurable surveillance and response capacity rather than only research or advisory activity.
The bill also adjusts how the statute describes who participates in setting the national strategy. Rather than tying strategy development to a particular named working group, the language removes that cross‑reference and shifts to a more flexible description of participants.
Practically, that gives the responsible agencies discretion to change the roster of contributors, whether to include new technical experts, representatives from affected communities, or different federal partners.Finally, the bill extends the statutory authorization that enables grants and other supports for state and local public health capacity and the regional centers. Because the text does not designate appropriation amounts, maintaining program activity will still require future funding actions by Congress.
In short, the measure preserves and modestly refocuses legal authority while leaving the money and operational specifics to agencies and appropriators.
The Five Things You Need to Know
The bill amends section 317U(b) of the Public Health Service Act by striking the cross‑reference to the Tick‑Borne Disease Working Group established under section 2062 of the 21st Century Cures Act and replacing that clause with the phrase “appropriate individuals.”, It inserts into section 317U(c)(4) an explicit operational objective: activities “including by increasing capacity to identify, report, prevent, and respond to such diseases.”, The bill replaces the authorization period language in section 317U(f) — previously “2021 through 2025” — with a new authorization window of “2026 through 2030.”, It makes the same five‑year extension in section 2822(c) of the Public Health Service Act, changing that provision’s authorization period from “2021 through 2025” to “2026 through 2030.”, All changes are textual and narrowly scoped: the bill does not create new programs or specify appropriation amounts, it only updates statutory language and extends existing authorization windows.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Removes a statutory cross‑reference to a specific working group
This amendment deletes a line that tied the statute’s advisory roster to the Tick‑Borne Disease Working Group created by the 21st Century Cures Act and replaces it with a generic reference to “appropriate individuals.” That mechanical change reduces the statute’s dependence on a particular congressionally established group and gives the implementing agency discretion to determine who should advise or participate in strategy development. Practically, agencies could broaden or narrow participants without a further statutory fix; critics will view that as flexibility, supporters as a loss of an explicit stakeholder anchor.
Adds operational readiness language to program objectives
The bill adds text to an enumerated program objective to emphasize building capacity to identify, report, prevent, and respond to vector‑borne diseases. That shifts the statutory emphasis from high‑level strategy and research toward operational public health functions—surveillance systems, laboratory capacity, reporting pipelines, prevention programs, and response readiness. Agencies implementing the statute will need to interpret that language when setting grant priorities, performance metrics, and technical assistance.
Extends statutory authorization windows for covered programs
The bill lengthens the authorization period for the national strategy/regional center authority and the enhanced support authority for health departments by five years. This preserves the statutory authority that permits ongoing grant and program activity but does not itself appropriate funds. Continuation of actual program funding remains subject to future appropriations and agency budgeting choices.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at risk of or suffering from tick‑borne diseases — clearer statutory emphasis on detection and response can translate into faster diagnosis, better surveillance, and more targeted prevention in communities where ticks are spreading.
- State and local health departments — the statutory focus on operational capacity aligns program objectives with the needs of departments that run surveillance, testing, and outbreak response, potentially improving eligibility for technical assistance and grants.
- Regional Centers of Excellence and academic partners — continued authorization preserves the institutional platform for coordinated research, clinical guidance, and training that those centers provide.
- Public health and clinical laboratories — the bill’s operational focus supports investments in laboratory capacity and standardized reporting that labs need to detect and confirm emerging tick‑borne infections.
Who Bears the Cost
- Federal implementing agencies (e.g., CDC) — agencies must translate broader operational language into grant programs, guidance, and monitoring frameworks with existing staff and budgets, increasing administrative workload.
- State and local health departments — meeting expanded expectations for surveillance and response may require investments in workforce, lab partnerships, IT, and reporting that departments must fund or seek through competitive grants.
- Regional centers and academic grantees — to remain competitive for federal support they may need to reorient proposals toward operational deliverables, which can require reallocating research agendas and infrastructure.
- Congress/appropriators — although the statute is reauthorized, sustaining activities depends on future appropriations; funding decisions will compete with other public health priorities.
Key Issues
The Core Tension
The central tension is between flexibility and accountability: the bill gives implementing agencies freedom to adjust who shapes the national strategy and how funds are targeted, while simultaneously raising legitimate concerns that removing explicit stakeholder anchors and leaving operational expectations undefined will make it harder to ensure consistent, well‑funded protections for communities affected by tick‑borne diseases.
The bill trades statutory specificity for administrative flexibility. Removing the explicit cross‑reference to the Tick‑Borne Disease Working Group gives agencies leeway to set advisory membership, but it also removes a statutorily named forum that advocates and clinicians previously used to ensure visibility.
That change raises questions about who will represent patient perspectives and how advisory input will be documented.
Adding operational language (identify, report, prevent, respond) clarifies Congress’s expectation that programs support day‑to‑day public health functions. But the statute does not define metrics, timelines, or minimum capacity thresholds; translating that language into measurable grant criteria will fall to agencies already constrained by budget and competing priorities.
Finally, extending authorization windows preserves legal authority but without appropriation text; program continuity therefore depends on future funding decisions and interagency prioritization, which could create gaps between statutory intent and on‑the‑ground capacity.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.